{"id":"W2947828388","doi":"10.1200/jco.2019.37.15_suppl.tps601","title":"KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Pembrolizumab; Breast cancer; Epirubicin; Placebo; Oncology; Chemotherapy; Neoadjuvant therapy; Anthracycline; Cancer; Gastroenterology; Urology; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001362518,0.0005315024,0.003232697,0.0001206273,0.0001566293,0.00002434525,0.0003550497,0.0003308112,0.0001871884],"category_scores_gemma":[0.0002583728,0.0003506867,0.0005497971,0.0001250893,0.0005841146,0.00004010144,0.000109194,0.0005852014,0.000002038176],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000122462,"about_ca_system_score_gemma":0.0006067261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001487236,"about_ca_topic_score_gemma":0.0002904669,"domain_scores_codex":[0.9951813,0.001136742,0.002156902,0.000668398,0.0003897772,0.0004669447],"domain_scores_gemma":[0.9931616,0.001567397,0.003564838,0.000353341,0.001058543,0.0002942942],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8585005,0.005410104,0.1088162,0.00002785287,0.005656661,0.00001764007,0.0005336676,0.0000248239,0.002376918,0.00004543494,0.000240818,0.01834936],"study_design_scores_gemma":[0.7972684,0.0682257,0.1152923,0.0000662567,0.0005348127,0.00004833197,0.0004014887,0.000009325379,0.01733398,0.00004097141,0.00042798,0.0003504682],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932042,0.00056676,0.0001224482,0.001731793,0.0005653462,0.003316188,0.0004404619,0.00001046864,0.00004227744],"genre_scores_gemma":[0.9936709,0.003765811,0.0009739081,0.0003163859,0.0007460756,0.0002454962,0.00005074071,0.0000748178,0.0001558139],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0628156,"threshold_uncertainty_score":0.9998945,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03627296762888955,"score_gpt":0.3865373696550671,"score_spread":0.3502644020261776,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}